Key Takeaways Casgevy, CRSP's first marketed therapy, treats SCD and TDT but saw just $10 million in 2024 sales. The therapy's complex, multi-step process has slowed adoption despite its curative potential. Casgevy faces pressure from cheaper approved drugs and emerging gene-editing competitors.CRISPR Therapeutics’ (CRSP) first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell dis ...